Madrigal Pharmaceuticals (MDGL) Competitors $440.36 -2.98 (-0.67%) As of 11:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, IONS, HALO, and RGENShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Its Competitors Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Ionis Pharmaceuticals Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Do insiders and institutionals have more ownership in BIIB or MDGL? 87.9% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, BIIB or MDGL? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.08$1.63B$10.4613.10Madrigal Pharmaceuticals$180.13M54.33-$465.89M-$12.85-34.31 Does the media favor BIIB or MDGL? In the previous week, Biogen had 28 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 31 mentions for Biogen and 3 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 0.66 beat Madrigal Pharmaceuticals' score of 0.58 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 10 Very Positive mention(s) 8 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BIIB or MDGL more profitable? Biogen has a net margin of 15.31% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Biogen's return on equity of 13.85% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Madrigal Pharmaceuticals -54.68%-38.38%-27.32% Do analysts recommend BIIB or MDGL? Biogen presently has a consensus price target of $181.65, indicating a potential upside of 32.59%. Madrigal Pharmaceuticals has a consensus price target of $483.38, indicating a potential upside of 9.65%. Given Biogen's higher possible upside, equities analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more volatility and risk, BIIB or MDGL? Biogen has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500. SummaryBiogen beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.80B$2.54B$5.72B$10.40BDividend YieldN/A53.63%5.53%4.58%P/E Ratio-34.3723.6076.4326.62Price / Sales54.33521.29472.7192.34Price / CashN/A171.0137.4661.85Price / Book12.745.3713.276.45Net Income-$465.89M$32.95M$3.29B$271.39M7 Day Performance5.61%4.01%2.60%3.06%1 Month Performance6.31%5.96%4.65%7.62%1 Year Performance97.62%1.93%74.34%30.20% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals3.901 of 5 stars$440.36-0.7%$483.38+9.8%+96.4%$9.78B$180.13M-34.2790BIIBBiogen4.6526 of 5 stars$143.32-1.1%$181.65+26.7%-28.9%$21.24B$9.68B13.707,605Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.5242 of 5 stars$403.11-0.5%$438.85+8.9%+22.1%$18.27B$2.88B15.731,305Insider TradeINCYIncyte4.7613 of 5 stars$83.14+0.0%$82.53-0.7%+31.8%$16.23B$4.24B18.902,617Analyst ForecastNBIXNeurocrine Biosciences4.4463 of 5 stars$140.44-1.0%$160.00+13.9%+24.3%$14.07B$2.36B41.551,800Positive NewsAnalyst ForecastEXELExelixis4.6648 of 5 stars$39.01-0.4%$44.06+12.9%+51.0%$10.54B$2.17B18.751,147Positive NewsBMRNBioMarin Pharmaceutical4.9638 of 5 stars$53.14-1.8%$92.04+73.2%-22.7%$10.39B$2.85B15.773,040Positive NewsEXASExact Sciences4.7818 of 5 stars$53.43-0.9%$68.05+27.4%-24.7%$10.21B$2.76B-9.847,000Positive NewsIONSIonis Pharmaceuticals3.9851 of 5 stars$61.10-3.3%$67.88+11.1%+49.6%$10.07B$705M-33.211,069Trending NewsAnalyst ForecastHALOHalozyme Therapeutics4.5572 of 5 stars$76.33-0.7%$67.11-12.1%+32.5%$8.99B$1.02B17.47390Positive NewsAnalyst ForecastInsider TradeRGENRepligen4.8802 of 5 stars$113.74+0.2%$166.67+46.5%-11.7%$6.39B$634.44M-454.941,778Analyst Upgrade Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors Incyte Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Ionis Pharmaceuticals Competitors Halozyme Therapeutics Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDGL) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDGL Stock Alerts